Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets
- 30 September 2009
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 71 (3), 181-198
- https://doi.org/10.1016/j.critrevonc.2008.10.011
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitorBlood, 2008
- Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targetsJCI Insight, 2007
- Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypesBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphomaBritish Journal of Haematology, 2006
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphomaJournal of the American Academy of Dermatology, 2005
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- The Hallmarks of CancerCell, 2000
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995